Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1–positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States
Oliver Hale, K. Patterson, Yizhen Lai, Yang Meng, Haojie Li, James Luke Godwin, Blanca Homet Moreno, Ronac Mamtani
Topics & Concepts
MedicinePembrolizumabCarboplatinMetastatic Urothelial CarcinomaOncologyUrothelial carcinomaUrothelial cancerCisplatinChemotherapyInternal medicineCancerImmunotherapyBladder cancerBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersEsophageal Cancer Research and Treatment